| 1. |
|
|
| 2. |
|
|
| 3. |
- Biemann, R., et al.
(författare)
-
Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial
- 2016
-
Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 6
-
Tidskriftsartikel (refereegranskat)abstract
- Bile acids (BAs) are increasingly recognised as metabolic regulators, potentially improving insulin sensitivity following bariatric surgery. However, physiological relevance of such observations remains unknown. Hence, we analysed serum BA composition and associated gut-derived hormone levels following lifestyle-induced weight loss in individuals with metabolic syndrome (MetS). 74 non-smoking men (45-55 yr) with MetS were randomised to a lifestyle-induced weight loss program (supervision via telemonitoring) or to a control arm. Before and after a 6 months intervention period clinical and laboratory parameters, body composition, serum BA profile, FGF-19, and GLP-1 concentrations were determined in fasting blood samples. 30 participants in the control and 33 participants in the treatment arm completed the study and were included in the data analysis. In participants of the treatment arm lifestyle-induced weight loss resulted in markedly improved insulin sensitivity. Serum levels of BA species and total GLP-1 decreased, while FGF-19 remained stable. Serum BA composition changed towards an increased 12 alpha-hydroxylated/non-12 alpha-hydroxylated ratio. None of these parameters changed in participants of the control arm. Our results demonstrate that improved metabolic control by lifestyle modifications lowers serum levels of BAs and GLP-1 and changes serum BA composition towards an increased 12 alpha/non-12 alpha ratio (ICTRP Trial Number: U1111-1158-3672).
|
|
| 4. |
- Merker, L, et al.
(författare)
-
Nephropathy for Patients with Diabetes
- 2019
-
Ingår i: DIABETOLOGIE UND STOFFWECHSEL. - : Georg Thieme Verlag KG. - 1861-9002 .- 1861-9010. ; 14, s. S235-S239
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
- Merker, L, et al.
(författare)
-
Nephropathy for Patients with Diabetes
- 2021
-
Ingår i: DIABETOLOGIE UND STOFFWECHSEL. - : Georg Thieme Verlag KG. - 1861-9002 .- 1861-9010. ; 16, s. S324-S328
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 6. |
- Merker, L, et al.
(författare)
-
Nephropathy in diabetes
- 2020
-
Ingår i: DIABETOLOGE. - : Springer Science and Business Media LLC. - 1860-9716. ; 16:5, s. 510-514
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
- Merker, L, et al.
(författare)
-
Nephropathy in diabetes
- 2021
-
Ingår i: DIABETOLOGE. - : Springer Science and Business Media LLC. - 1860-9716. ; 17:2, s. 175-178
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
- Merker, L, et al.
(författare)
-
Nephropathy in Diabetes
- 2021
-
Ingår i: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. - : Georg Thieme Verlag KG. - 1439-3646. ; 129:S 01, s. S60-S63
-
Tidskriftsartikel (refereegranskat)
|
|
| 9. |
- Merker, L, et al.
(författare)
-
Nephropathy in diabetes
- 2022
-
Ingår i: DIABETOLOGE. - : Springer Science and Business Media LLC. - 1860-9716. ; 18:3, s. 284-288
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 10. |
- Merker, L, et al.
(författare)
-
Nephropathy in Patients with Diabetes
- 2020
-
Ingår i: DIABETOLOGIE UND STOFFWECHSEL. - : Georg Thieme Verlag KG. - 1861-9002 .- 1861-9010. ; 15, s. S170-S174
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 11. |
- Zimmermann, S, et al.
(författare)
-
The Extent of Lifestyle-Induced Weight Loss Determines the Risk of Prediabetes and Metabolic Syndrome Recurrence during a 5-Year Follow-Up
- 2022
-
Ingår i: Nutrients. - : MDPI AG. - 2072-6643. ; 14:15
-
Tidskriftsartikel (refereegranskat)abstract
- It is controversial whether lifestyle-induced weight loss (LIWL) intervention provides long-term benefit. Here, we investigated whether the degree of weight loss (WL) in a controlled LIWL intervention study determined the risk of prediabetes and recurrence of metabolic syndrome (MetS) during a 5-year follow-up. Following LIWL, 58 male participants (age 45–55 years) were divided into four quartiles based on initial WL: Q1 (WL 0–8.1%, n = 15), Q2 (WL 8.1–12.8%, n = 14), Q3 (WL 12.8–16.0%, n = 14), and Q4 (WL 16.0–27.5%, n = 15). We analyzed changes in BMI, HDL cholesterol, triglycerides (TGs), blood pressure, and fasting plasma glucose (FPG) at annual follow-up visits. With a weight gain after LIWL between 1.2 (Q2) and 2.5 kg/year (Q4), the reduction in BMI was maintained for 4 (Q2, p = 0.03) or 5 (Q3, p = 0.03; Q4, p < 0.01) years, respectively, and an increase in FPG levels above baseline values was prevented in Q2–Q4. Accordingly, there was no increase in prediabetes incidence after LIWL in participants in Q2 (up to 2 years), Q3 and Q4 (up to 5 years). A sustained reduction in MetS was maintained in Q4 during the 5-year follow-up. The present data indicate that a greater initial LIWL reduces the risk of prediabetes and recurrence of MetS for up to 5 years.
|
|
